RAD001, everolimus ( DrugBank: Everolimus )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 34 | Neurofibromatosis | 1 |
34. Neurofibromatosis
Clinical trials : 137 / Drugs : 213 - (DrugBank : 76) / Drug target genes : 87 - Drug target pathways : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01345136 (ClinicalTrials.gov) | July 1, 2015 | 21/4/2011 | Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma | A Single Arm, Monocenter Phase II Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis Type 2 - Related Vestibular Schwannoma | Neurofibromatosis Type 2;Neuroma, Acoustic | Drug: RAD001, everolimus | Jonsson Comprehensive Cancer Center | Novartis Pharmaceuticals | Active, not recruiting | 16 Years | 65 Years | All | 4 | Phase 2 | United States |